Search

everythinglearnresearchcommunity

for

Search:↓

Mechlorethamine treatment regrew hair in mice by killing immune cells causing hair loss without harming hair follicles.

XEDAR triggers a specific signaling pathway in cells.

Hormone imbalances can cause skin diseases, and understanding these links is important for diagnosis and treatment.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

Platelet-Rich Plasma (PRP) could potentially help regrow hair in people with Alopecia Areata, but more research is needed to confirm its effectiveness.

Polycystic ovary syndrome is a common hormonal disorder in women, linked to increased risk of metabolic and heart diseases, and needs more research for better understanding and treatment.

Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.

Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.

Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.

Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.

CBG may help with various medical conditions but needs more human research to confirm safety and effectiveness.

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.

COVID-19 can directly trigger certain skin conditions like pustular dermatoses due to an inflammatory response.

Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.

Skin changes can indicate hormonal imbalances and help diagnose endocrine disorders.

People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.

Special and immunohistochemical stains are not routinely needed for diagnosing hair disorders.

Genetic mutation and carcinogen treatment are both needed for skin cancer to develop in these specific mice.

Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.

Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.

Burn scars heal abnormally and more research is needed to find better treatments.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

Damaged hair follicles make mice more prone to skin inflammation and skin cancer after UV exposure.

A five-month-old boy with Omenn syndrome successfully recovered after a stem cell transplant with reduced intensity conditioning.

Combining Cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata.

Hair loss can be caused by stress, infections, drugs, and various diseases, with treatment depending on accurate diagnosis.

New topical treatment using spherical nucleic acids shows promise in reducing psoriasis inflammation.

Nail loss may be a side effect of the MS drug teriflunomide.